Macrophage-Targeted Lung Delivery of Dexamethasone Improves Pulmonary Fibrosis Therapy via Regulating the Immune Microenvironment.
Macrophage-Targeted Lung Delivery of Dexamethasone Improves Pulmonary Fibrosis Therapy via Regulating the Immune Microenvironment.
复制标题
巨噬细胞靶向肺给药地塞米松通过调节免疫微环境改善肺纤维化治疗。
DOI:
10.3389/fimmu.2021.613907
复制
发表时间:
2021
影响因子:
7.3
通讯作者:
Yang J
中科院分区:
文献类型:
--
作者:
Sang X;Wang Y;Xue Z;Qi D;Fan G;Tian F;Zhu Y;Yang J
Idiopathic pulmonary fibrosis (IPF) is serious chronic lung disease with limited therapeutic approaches. Inflammation and immune disorders are considered as the main factors in the initiation and development of pulmonary fibrosis. Inspired by the key roles of macrophages during the processes of inflammation and immune disorders, here, we report a new method for direct drug delivery into the in-situ fibrotic tissue sites in vitro and in vivo. First, liposomes containing dexamethasone (Dex-L) are prepared and designed to entry into the macrophages in the early hours, forming the macrophages loaded Dex-L delivery system (Dex-L-MV). Chemokine and cytokine factors such as IL-6, IL-10, Arg-1 are measured to show the effect of Dex-L to the various subtypes of macrophages. Next, we mimic the inflammatory and anti-inflammatory microenvironment by co-culture of polarized/inactive macrophage and fibroblast cells to show the acute inflammation response of Dex-L-MV. Further, we confirm the targeted delivery of Dex-L-MV into the inflammatory sites in vivo, and surprisingly found that injected macrophage containing Dex can reduce the level of macrophage infiltration and expression of the markers of collagen deposition during the fibrotic stage, while causing little systematic toxicity. These data demonstrated the suitability and immune regulation effect of Dex-L-MV for the anti-pulmonary process. It is envisaged that these findings are a step forward toward endogenous immune targeting systems as a tool for clinical drug delivery.
登录
查看更多内容
DOI:
10.1084/jem.20162152
发表时间:
2017-08-07
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Misharin AV;Morales-Nebreda L;Reyfman PA;Cuda CM;Walter JM;McQuattie-Pimentel AC;Chen CI;Anekalla KR;Joshi N;Williams KJN;Abdala-Valencia H;Yacoub TJ;Chi M;Chiu S;Gonzalez-Gonzalez FJ;Gates K;Lam AP;Nicholson TT;Homan PJ;Soberanes S;Dominguez S;Morgan VK;Saber R;Shaffer A;Hinchcliff M;Marshall SA;Bharat A;Berdnikovs S;Bhorade SM;Bartom ET;Morimoto RI;Balch WE;Sznajder JI;Chandel NS;Mutlu GM;Jain M;Gottardi CJ;Singer BD;Ridge KM;Bagheri N;Shilatifard A;Budinger GRS;Perlman H
通讯作者:
Perlman H
影响因子:
9.5
作者:
Xuan, Mingjun;Shao, Jingxin;He, Qiang
通讯作者:
He, Qiang
影响因子:
10.6
作者:
Chanda D;Otoupalova E;Smith SR;Volckaert T;De Langhe SP;Thannickal VJ
通讯作者:
Thannickal VJ
影响因子:
10.8
作者:
Ayer, Maxime;Klok, Harm-Anton
通讯作者:
Klok, Harm-Anton
影响因子:
12.4
作者:
Tang, Tao-Tao;Lv, Lin-Li;Liu, Bi-Cheng
通讯作者:
Liu, Bi-Cheng